Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Consolidated Statements of Operations
Net Revenues	$ 48,625	$ 48,470	$ 103,146	$ 98,244
Operating Expenses
Cost of sales (excluding depreciation and amortization)	22,314	20,695	42,299	42,499
Research and development	2,805	3,035	5,773	9,379
Selling, general, and administrative	18,820	21,213	36,407	34,896
Depreciation and amortization	11,324	11,198	22,222	22,381
Legal settlement expense	8,400		8,400	0
Cortrophin pre-launch charges	515	3,636	553	8,238
Total Operating Expenses	64,178	59,777	115,654	117,393
Operating Loss	(15,553)	(11,307)	(12,508)	(19,149)
Other Expense, net
Interest expense, net	(2,531)	(2,356)	(4,985)	(4,388)
Other expense, net	(67)	(116)	(582)	(106)
Loss Before Benefit for Income Taxes	(18,151)	(13,779)	(18,075)	(23,643)
Benefit for income taxes	4,045	1,443	4,055	4,296
Net Loss	$ (14,106)	$ (12,336)	$ (14,020)	$ (19,347)
Basic and Diluted Loss Per Share:
Basic Loss Per Share	$ (1.17)	$ (1.03)	$ (1.16)	$ (1.62)
Diluted Loss Per Share	$ (1.17)	$ (1.03)	$ (1.16)	$ (1.62)
Basic Weighted-Average Shares Outstanding	12,085	11,967	12,045	11,935
Diluted Weighted-Average Shares Outstanding	12,085	11,967	12,045	11,935